Do Oral Steroid Dose Packs Predict How Well Epidural Steroid Injections Will Work?

Oral Steroid Dose Pack Used As A Predictor For The Effectiveness Of Epidural Steroid Injections

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02026726

Enrollment

Registered

2014-01-03

Start date

2011-11-30

Completion date

2020-08-21

Last updated

2020-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Spine Disc Herniation

Brief summary

The purpose of this observational study is to show whether a standard oral steroid dose pack can be used as a screening tool to assess the effectiveness of a subsequent epidural steroid injection (ESI). If an oral steroid does not give a patient significant temporary relief of pain from a herniated lumbar disc then an epidural steroid injection will not either. Therefore the risk and expense associated from the interventional pain management procedure for those patients could be avoided and other treatment modalities pursued.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years and older * Diagnosed by participating physicians during the study enrollment period as having intervertebral disk herniation and persistent symptoms with or without some nonoperative treatment for at least 4 weeks * Radicular pain (below the knee for lower lumbar herniations, into the anterior thigh for upper lumbar herniations) * Evidence of nerve-root irritation with a positive nerve-root tension sign (straight leg raise-positive between 30° and 70°) or a corresponding neurologic deficit (asymmetrical depressed reflex, decreased sensation in a dermatomal distribution) * Undergone either MRI or CT scan showing disc herniation (protrusion, extrusion, or sequestered fragment) at a level and side corresponding to the clinical symptoms * Patients with multiple herniations can be included if only one of the herniations is considered symptomatic * Preenrollment nonprocedural care can include: education/counseling, physical therapy, chiropractic therapy, anti-inflammatory medications, opioid analgesics, adjuvant analgesics such as anticonvulsants and antidepressants

Exclusion criteria

* Prior lumbar surgery * Cauda equina syndrome * Vertebral fractures * Spine infection or tumor * Severe motor deficit * Inflammatory spondyloarthropathy * Pregnancy * Cardiac or pulmonary comorbid conditions contraindicating interventional procedures * Diabetes * Inability/unwillingness to have spinal injections

Design outcomes

Primary

Measure	Time frame	Description
Change in Patient-Reported Pain	Baseline,1 wk post oral steroid completion, 2 wks post ESI #1, 2 wks post ESI #2, 2 wks post ESI #3, then at 6 wks, 12 wks, 6 mo. & 12 mo. after last transforaminal ESI (TRESI).	The primary endpoint will be a patient-reported pain as measured by a 10 cm visual analog scale (VAS) with 0 being no pain and 10 being the most severe pain imaginable.

Countries

United States

Outcome results